LabCorp is Scheduled to Present at the Bank of America 38th Annual Investment Conference

BURLINGTON, N.C.--(BUSINESS WIRE)--Sept. 15, 2008--Laboratory Corporation of America(R) Holdings (LabCorp(R)) (NYSE: LH) today announced that David P. King, Chief Executive Officer and William B. (Brad) Hayes, Executive Vice President and Chief Financial Officer, are scheduled to speak at the Bank

LabCorp's Liquid Yield Option(TM) Notes Due 2021 and Zero Coupon Convertible Subordinated Notes Due 2021 to Accrue Contingent Interest

BURLINGTON, N.C.--(BUSINESS WIRE)--Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH - News) announced today that for the period of September 12, 2008 to March 11, 2009, its zero coupon subordinated Liquid Yield Option™ Notes due 2021 (LYONs) and Zero Coupon Convertible Subordinated

LabCorp is Scheduled to Present at the Bank of America 2008 Specialty Pharmaceuticals Conference

BURLINGTON, N.C.--(BUSINESS WIRE)--Aug. 6, 2008--Laboratory Corporation of America(R) Holdings (LabCorp(R)) (NYSE: LH) today announced that Bradford T. Smith, Executive Vice President, Corporate Affairs, and Andrew J. Conrad, Ph.D., Chief Scientist and Global Head of Clinical Trials for LabCorp,

LabCorp Launches Chronic Kidney Disease Program

National Kidney Foundation One of Many Partners BURLINGTON, N.C.--(BUSINESS WIRE)--Aug. 6, 2008--Laboratory Corporation of America(R) Holdings (LabCorp(R)) (NYSE:LH) today announced the launch of a national effort to combat chronic kidney disease (CKD) in North America. U.S.

Laboratory Corporation of America(R) Holdings Announces 2008 Second Quarter Results

Growth in Testing Volume and Price Drives Industry-Leading Margins and $194.7 Million in Operating Cash Flow BURLINGTON, N.C.--(BUSINESS WIRE)--July 24, 2008--Laboratory Corporation of America(R) Holdings (LabCorp(R)) (NYSE: LH) today announced results for the quarter ended June 30, 2008.

LabCorp Announces Availability of ColoSure(TM)

Among the Most Sensitive In-Guideline Non-invasive Colorectal Cancer Screening Methods BURLINGTON, N.C., Jul 14, 2008 (BUSINESS WIRE) -- Laboratory Corporation of America(R) Holdings (LabCorp(R)) (NYSE:LH) is now offering ColoSure(TM), among the most sensitive, in-guideline non-invasive colorectal

Conversion Right Triggered for LabCorp's Liquid Yield Option(TM) Notes Due 2021 and Zero Coupon Convertible Subordinated Notes Due 2021

BURLINGTON, N.C., Jul 01, 2008 (BUSINESS WIRE) -- Laboratory Corporation of America(R) Holdings (LabCorp(R)) (NYSE: LH) announced today that its zero coupon subordinated Liquid Yield Option(TM) Notes due 2021 (LYONs) and Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) may be

LabCorp Announces Availability of OvaSure(TM)

Ovarian Cancer Test For High-Risk Women BURLINGTON, N.C.--(BUSINESS WIRE)--June 23, 2008--Laboratory Corporation of America(R) Holdings (LabCorp(R)) (NYSE: LH) is now offering OvaSure(TM), an Ovarian Cancer Screening test to assess the presence of early stage ovarian cancer in high-risk women.

LabCorp is Scheduled to Present at the 18th Annual Wachovia Nantucket Equity Conference

BURLINGTON, N.C.--(BUSINESS WIRE)--June 23, 2008--Laboratory Corporation of America(R) Holdings (LabCorp(R)) (NYSE: LH) today announced that David P. King, Chief Executive Officer, is scheduled to speak at the 18th Annual Wachovia Nantucket Equity Conference in Nantucket, MA.

LabCorp is Scheduled to Present at the Jefferies 2nd Annual Healthcare Conference

BURLINGTON, N.C.--(BUSINESS WIRE)--June 20, 2008--Laboratory Corporation of America(R) Holdings (LabCorp(R)) (NYSE:LH) today announced that David P. King, Chief Executive Officer and Bradford T. Smith, Executive Vice President, Corporate Affairs, are scheduled to speak at the Jefferies 2nd Annual